Johnson & Johnson Reports Q3 2026 Results with Vision Care Growth and Raises Full-Year Guidance

Johnson & Johnson reported Q3 2026 financial results, showing a 5.9 percent increase in worldwide sales to $25.4 billion. Within the MedTech segment, vision care grew 4.4 percent on a reported basis and 5.1 percent operationally, primarily driven by strong contact lens sales, particularly the Acuvue Oasys 1-Day family. Surgical Vision also rose 7.1 percent, supported by demand for premium intraocular lenses like Tecnis PureSee and Tecnis Odyssey, which surpassed 1 million implants worldwide. The company received CE marking for Acuvue Oasys Max 2-Week reusable lenses in Europe. Consequently, J&J raised its full-year sales forecast to $101.0–$101.4 billion. Additionally, CFO Joe Wolk confirmed plans to separate the orthopedics business by mid-2027, while MedTech leadership acknowledged performance below internal standards.